Ticker LaunchIPO · IMRA
Enliven Therapeutics, Inc.
Formerly IMARA Inc.
Enliven Therapeutics, Inc. (IMRA) priced its initial public offering on Mar 12, 2020 at $16.00 per share, within its $16.00–$18.00 range, raising $75.2M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $265.2M. WilmerHale advised the company and Cooley advised the underwriters.
At its 2020 IPO, IMARA Inc. (now Enliven Therapeutics, Inc.) was a clinical-stage biopharmaceutical company developing treatments for hemoglobinopathies. Its sole product candidate, IMR-687, is an oral once-daily treatment for sickle cell disease and beta-thalassemia.
- Status
- IPO
- Ticker
- IMRA
- Exchange
- Nasdaq Global Select
- Priced
- Mar 12, 2020
- IPO price
- $16.00
- Price range
- $16.00–$18.00
- Raised
- $75.2M
- Market cap at IPO price
- $265.2M
- First filed
- Feb 14, 2020
- Company counsel
- WilmerHale
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Feb 14, 2020
- Latest amendment Mar 10, 2020
- Final prospectus (424B4) Mar 12, 2020
- All filings on EDGAR CIK 1672619
Other Biotech & pharma IPOs in 2020
- Keros Therapeutics, Inc.KROS · Apr 8, 2020 · $96M
- Zentalis Pharmaceuticals, Inc.ZNTL · Apr 6, 2020 · $165.2M
- Passage BIO, Inc.PASG · Feb 28, 2020 · $216M
- Revolution Medicines, Inc.RVMD · Feb 13, 2020 · $238M
- Beam Therapeutics Inc.BEAM · Feb 7, 2020 · $180M
- PPD, Inc.PPD · Feb 6, 2020 · $1.62B